Get the Stockscreener App
0.8764
3.35%
0.0284
After Hours:
.88
0.0036
+0.41%
Revelation Biosciences Inc stock is traded at $0.8764, with a volume of 36,406.
It is up +3.35% in the last 24 hours and up +6.63% over the past month.
Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of therapies for the prevention and treatment of disease using trained immunity. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$0.848
Open:
$0.83
24h Volume:
36,406
Relative Volume:
0.02
Market Cap:
$3.19M
Revenue:
-
Net Income/Loss:
$-120.30K
P/E Ratio:
-1.5932
EPS:
-0.5501
Net Cash Flow:
$-7.29M
1W Performance:
+5.32%
1M Performance:
+6.63%
6M Performance:
-63.02%
1Y Performance:
-95.06%
1-Day Range:
$0.83
$0.88
1-Week Range:
$0.821
$0.88
52-Week Range:
$0.702
$25.26
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Revelation Biosciences Inc Stock (REVB) Latest News
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences faces Nasdaq delisting over noncompliance - Investing.com India
United States shares lower at close of trade; Dow Jones Industrial Average down 0.43% - MSN
ROTH to Host 3rd Annual Healthcare Opportunities Conference on October 9 in New York City - The Manila Times
A better buy-in window may exist right now for Revelation Biosciences Inc (REVB) - SETE News
Revelation Biosciences Inc Inc. (REVB) Price Performance: A Guide to Technical Indicators - The InvestChronicle
Farallon Capital Management LLC Boosts Stake in Revolution Medicines, Inc. (NASDAQ:RVMD) - MarketBeat
Revolution Medicines added to Analyst Focus List at JPMorgan - TipRanks
Revelation Biosciences’ Gemini Induces Dose Dependent Significant Increases in IL-10 - Morningstar
Revolution Medicines, Inc. (NASDAQ:RVMD) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Revolution Medicines (NASDAQ:RVMD) Trading Down 6.1% - MarketBeat
A stock that deserves closer examination: Revelation Biosciences Inc (REVB) - US Post News
Revance Therapeutics Shares Fall on Crown Labs Deal Delay - MarketWatch
Financial Fitness Check: Examining Revelation Biosciences Inc (REVB)’s Key Ratios - The Dwinnex
Revance Therapeutics plunges as Crown Labs tender offer delayed amid Teoxane dispute - Seeking Alpha
Revolve Group (NYSE:RVLV) Reaches New 1-Year High at $25.96 - Defense World
Revelation Biosciences stock hits 52-week low at $0.78 - Investing.com India
Revelation Biosciences stock hits 52-week low at $0.78 By Investing.com - Investing.com Australia
Revolution Medicines executive sells over $500k in company stock By Investing.com - Investing.com Canada
Revolution Medicines COO sells over $191k in company stock By Investing.com - Investing.com Canada
Revolution Medicines CFO sells over $99k in company stock - Investing.com India
Revolution Medicines executive sells over $200k in company stock - Investing.com
Revolution Medicines general counsel sells shares worth over $64k By Investing.com - Investing.com UK
Renovaro faces Nasdaq delisting over share price woes By Investing.com - Investing.com Australia
The growth track for Revolution Medicines Inc (RVMD) has changed recently - SETE News
Crown Labs tender offer for Revance delayed, expect deal to be completedanalyst - MSN
Revelation Pharma Announces Revelation Wholesale, an Extension of Its National Compounding Network - PR Newswire
455,099 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Bought by Sofinnova Investments Inc. - MarketBeat
Revolve Group (NYSE:RVLV) Trading Down 5.2% - MarketBeat
Revance Therapeutics falls as Crown Labs didn't start tender offer by deadline (update) - Seeking Alpha
RVLV stock soars to 52-week high, touches $24.67 - Investing.com
Financial Metrics Check: Revelation Biosciences Inc (REVB)’s Ratios for Trailing Twelve Months - The Dwinnex
United States shares higher at close of trade; Dow Jones Industrial Average up 0.14% - MSN
Revelation Biosciences announces warrant exercise and inducement - Investing.com India
Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds - Manchestertimes
Stock Performance Spotlight: Revelation Biosciences Inc (REVB) Ends the Day at 1.25, Down by -40.19 - The Dwinnex
Nasdaq Down Over 200 Points; Williams-Sonoma Shares Tumble After Q2 Results - Benzinga
Gold Down Over 1%; US Initial Jobless Claims Increase - Benzinga
Revelation Biosciences Inc [REVB] Stock trading around $2.09 per share: What’s Next? - The DBT News
Adversity is less terrifying than hope: Revelation Biosciences Inc (REVB) - SETE News
Microsoft seeks to win over new players at gamer gathering - Yahoo Finance UK
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility - Yahoo Finance
Keysight stock rising on Q3 earnings beat, upbeat guidance - Yahoo Finance
Uniti Group Inc. to Participate at the Citi 2024 Global TMT Conference - Yahoo Finance
Shein sues Temu alleging copyright infringement and fraud - Yahoo! Voices
Yacht insurance provider OMAC is hull carrier for sunken yacht in Sicily, sources say - Yahoo News UK
Ford delays BlueOval City truck launch date - Yahoo! Voices
RNC’s Latest Fundraising Is a Sign of How Much Trump Is Struggling - Yahoo! Voices
What is REVB’s price-to-sales ratio telling us about the company’s value? - US Post News
CONSOL Energy Inc. and Arch Resources merge to create Core Natural Resources - Yahoo News
Nvidia has a Buy rating from 66 analysts. Here's why - Yahoo Finance
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):